Idefirix (Imlifidase)

Imlifidase is an IgG‑degrading enzyme that cleaves human IgG antibodies at the hinge region. This enzymatic action splits each IgG molecule into Fab and Fc fragments, leading to a swift decline in serum IgG levels and a reduction in antibody‑mediated immune activity.

The dosing regimen for Idefirix is determined by the prescribing physician based on the patient’s clinical status, IgG levels, and transplant protocol. Specific dose amounts and infusion rates are individualized and should follow the authorized prescribing information.

Safety data for Idefirix in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with obstetric specialists.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Idefirix uniquely employs an IgG‑degrading enzyme, offering rapid and profound reduction of circulating IgG antibodies. Other agents, such as plasmapheresis or rituximab, work through different mechanisms and may require multiple sessions or longer timelines to achieve comparable desensitization.

Idefirix must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the product if it has been exposed to temperatures outside the recommended range.

Idefirix is given as an intravenous infusion under the supervision of qualified healthcare professionals. The infusion rate and duration are determined by the treating physician and are typically performed in a controlled clinical setting with monitoring for infusion‑related reactions.

Serious risks include anaphylaxis, severe cytokine release syndrome, thromboembolic events, and profound immunosuppression that can predispose patients to serious infections. Immediate medical attention is required if any signs of these reactions occur during or after infusion.

Idefirix should not be used in patients with known hypersensitivity to Imlifidase or any excipients, in those with active uncontrolled infections, or in individuals for whom rapid IgG depletion is contraindicated. The prescribing physician must evaluate each patient’s medical history before initiating therapy.